Last reviewed · How we verify
Victrelis (BOCEPREVIR)
Victrelis (BOCEPREVIR) is a small molecule Hepatitis C Virus NS3/4A Protease Inhibitor developed by MERCK SHARP DOHME. It targets Chymase and was FDA approved in 2011 for the treatment of chronic hepatitis C. As a patented medication, it is not yet available as a generic. Key safety considerations include potential interactions with other medications and monitoring for liver function. Victrelis is a critical component in the treatment of hepatitis C, but its use should be carefully managed due to its potential side effects.
At a glance
| Generic name | BOCEPREVIR |
|---|---|
| Sponsor | Merck & Co. |
| Drug class | Hepatitis C Virus NS3/4A Protease Inhibitor |
| Target | Chymase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 2011 |
Approved indications
- Chronic hepatitis C
Common side effects
Drug interactions
- CYP3A4 Substrates
- P-glycoprotein Substrates
- alfentanil
- alfuzosin
- alprazolam
- atazanavir
- atorvastatin
- bromocriptine
- buprenorphine
- cabergoline
- carbamazepine
- ciclosporin
Key clinical trials
- HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin (PHASE3)
- Grazoprevir (MK-5172) Administered With Peginterferon and Ribavirin in Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-003) (PHASE2)
- Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir.
- Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
- Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection (PHASE3)
- Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514) (PHASE3)
- The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160) (PHASE3)
- Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2) (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Victrelis CI brief — competitive landscape report
- Victrelis updates RSS · CI watch RSS
- Merck & Co. portfolio CI